Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

8.1K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II.

Leukemia·2026
Same author

A U1-U3 snRNA-snoRNA interaction couples SF3B1 mutation to chromatin-state rewiring and genome instability.

bioRxiv : the preprint server for biology·2026
Same author

All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Chromosome 5q deletion drives evolution of aneuploidy in myeloid neoplasms with complex karyotype.

Blood·2026
Same author

Development of CAR T cells Targeting a Surface RNA Binding Protein for the Treatment of Acute Leukemias.

Cancer discovery·2026
Same author

Outstanding Questions to Understand and Target Splicing Factor-Mutant Blood Cancers.

Blood cancer discovery·2026

Related Experiment Video

Updated: Sep 16, 2025

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

7.7K

An Isoform-Specific RUNX1C-BTG2 Axis Governs AML Quiescence and Chemoresistance.

Cuijuan Han1, Zhiping Zhang2, Edie I Crosse3

  • 1The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.

Blood Cancer Discovery
|July 9, 2025
PubMed
Summary

Aberrant RNA isoforms drive acute myeloid leukemia (AML) chemoresistance. Targeting the RUNX1C isoform reactivates quiescent cells, enhancing chemotherapy efficacy and potentially preventing AML recurrence.

More Related Videos

A Quantitative Assay to Study Protein:DNA Interactions, Discover Transcriptional Regulators of Gene Expression, and Identify Novel Anti-tumor Agents
06:43

A Quantitative Assay to Study Protein:DNA Interactions, Discover Transcriptional Regulators of Gene Expression, and Identify Novel Anti-tumor Agents

Published on: August 31, 2013

18.8K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

281

Related Experiment Videos

Last Updated: Sep 16, 2025

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

7.7K
A Quantitative Assay to Study Protein:DNA Interactions, Discover Transcriptional Regulators of Gene Expression, and Identify Novel Anti-tumor Agents
06:43

A Quantitative Assay to Study Protein:DNA Interactions, Discover Transcriptional Regulators of Gene Expression, and Identify Novel Anti-tumor Agents

Published on: August 31, 2013

18.8K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

281

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Epigenetics

Background:

  • Aberrant RNA isoforms are implicated in cancers like acute myeloid leukemia (AML).
  • The specific role of RNA isoforms in AML chemoresistance is not well understood.
  • Understanding these mechanisms is crucial for developing effective AML therapies.

Purpose of the Study:

  • To investigate the role of RNA isoform changes in AML chemoresistance.
  • To identify specific RNA isoforms and their regulatory mechanisms contributing to treatment failure.
  • To explore potential therapeutic strategies targeting identified RNA isoforms.

Main Methods:

  • Paired analysis of RNA isoform changes in AML patients before and after chemotherapy.
  • Identification of intragenic DNA methylation patterns.
  • RNA-based targeting strategies to modulate gene expression.

Main Results:

  • Intragenic DNA methylation at the RUNX1 proximal promoter elevated RUNX1C expression via an alternative distal promoter.
  • RUNX1C orchestrated an isoform-specific program promoting chemoresistance, involving BTG2.
  • BTG2 induced rRNA deadenylation, leading to decreased mRNA stability and increased cellular quiescence.
  • RNA-based targeting of RUNX1C reactivated quiescent cells and improved chemotherapy efficacy.

Conclusions:

  • RUNX1C is a key driver of AML chemoresistance and quiescence through BTG2.
  • Targeting RUNX1C with RNA-based therapies can overcome chemoresistance.
  • This approach offers a promising strategy to enhance AML treatment and prevent relapse.